FULL PAPERS
Copper-Catalyzed Domino Synthesis of Benzo[4,5]imidazo[1,2-a]pyrimidin-4(10H)-ones
2-(4-Chlorophenyl)-8-methylbenzo[4,5]imidazo[1,2-a]pyr-
Conclusions
imidin-4(10H)-one (2q): Eluent: DCM/PE/MeOH (5:5:1);
isolated yield: 67% (41.5 mg); yellow solid; mp 170–1728C;
1H NMR (400 MHz, DMSO-d6): d=8.31 (d, J=8.2 Hz, 1H),
8.00 (d, J=8.1 Hz, 2H), 7.32–7.27 (m, 3H), 7.14 (d, J=
8.2 Hz, 1H), 6.56 (s, 1H), 2.46 (s, 3H); 13C NMR (76 MHz,
DMSO-d6): d=161.1, 160.2, 150.0, 146.7, 136.5, 135.1, 131.3,
128.6 (2CH), 127.5 (2CH), 124.3, 123.3, 115.8, 111.5,
97.1, 21.9. ESI-MS: m/z=310.1, C17H13ClN3O [M+H]+.
We have developed a simple, efficient and practical
copper-catalyzed domino synthesis of benzo[4,5]im-
idazo[1,2-a]pyrimidin-4-ones, and the corresponding
target products were prepared in moderate to good
yields. The protocol uses N-(2-halophenyl)-3-alkylpro-
piolamides and cyanamide as the starting materials,
inexpensive CuI and pipecolinic acid as the catalyst
system, and the domino reactions underwent the se-
quential base-mediated Michael addition, nucleophilic
attack of NH to cyano and copper-catalyzed Ull-
mann-type coupling. The method exhibited some tol-
erance of functional groups, and the three-component
reaction extended the diversity of benzo[4,5]imid-
azo[1,2-a]pyrimidin-4(10H)-ones. Therefore, the pres-
ent method provides a novel strategy for synthesis of
nitrogen heterocycles.
Acknowledgements
The authors wish to thank the National Natural Science
Foundation of China (Grant Nos. 21172128, 21372139 and
21221062), and the Ministry of Science and Technology of
China (Grant No. 2012CB722605) for financial support.
References
[1] R. W. DeSimone, K. S. Currie, S. A. Mitchell, J. W.
Darrow, D. A. Pippin, Comb. Chem. High Throughput
Screening 2004, 7, 473.
Experimental Section
General Procedure
[2] P. D. Leeson, B. Springthorpe, Nat. Rev. Drug Discov-
A Schlenk tube was charged with the mixture of CuI
(0.02 mmol, 3.8 mg), pipecolinic acid (0.04 mmol, 5.2 mg),
Cs2CO3 (0.4 mmol, 130 mg) and N-(2-halophenyl)-3-phenyl-
ery 2007, 6, 881.
[3] a) A. W. White, R. Almassy, A. H. Calvert, N. J. Curtin,
R. J. Griffin, Z. Hostomsky, K. Maegley, D. R. Newell,
S. Srinivasan, B. T. Golding, J. Med. Chem. 2000, 43,
4084; b) N. H. Hauel, H. Nar, H. Priepke, U. Ries, J.
Stassen, W. Wienen, J. Med. Chem. 2002, 45, 1757.
[4] J. VelIk, V. Baliharova, J. Fink-Gremmels, S. Bull, J.
Lamka, L. Skalova, Res. Vet. Sci. 2004, 76, 95, and ref-
erences cited therein.
[5] M. Ulusoy, C. Zafer, C. Ozsoy, C. Varlikli, T. Dittrich,
B. Cetinkaya, S. Icli, Dyes. Pigm. 2010, 84, 88.
[6] S. W. Tsang, Y. Tao, Z. H. Lu, J. Appl. Phys. 2011, 109,
023711.
[7] For reviews, see a) J. A. Joule, K. Mills, in: Heterocyclic
Chemistry, 4th edn., Blackwell Science, Cambridge,
MA, 2000, p 194; b) K. Undheim, T. Benneche, in:
Comprehensive Heterocyclic Chemistry II, (Eds.: A. R.
Katritzky, C. W. Rees, E. F. V. Scriven, A. McKillop),
Pergamon, Oxford, 1996, Vol. 6, p 93; c) I. M. Lagoja,
Chem. Biodiversity 2005, 2, 1; d) J. P. Michael, Nat.
Prod. Rep. 2005, 22, 627; e) A. W. Erian, Chem. Rev.
1993, 93, 1991.
[8] a) D. J. Hazuda, P. Felock, M. Witmer, A. Wolfe, K.
Stillmock, J. A. Grobler, A. Espeseth, L. Gabryelski,
W. Schleif, C. Blau, M. D. Miller, Science 2000, 287,
646; b) D. J. Hazuda, S. D. Young, J. P. Guare, N. J. An-
thony, R. P. Gomez, J. S. Wai, J. P. Vacca, L. Handt,
S. L. Motzel, H. J. Klein, G. Dornadula, R. M. Dano-
vich, M. V. Witmer, K. A. Wilson, L. Tussey, W. A.
Schleif, L. S. Gabryelski, L. Jin, M. D. Miller, D. R. Ca-
simiro, E. A. Emini, J. W. Shiver, Science 2004, 305,
528.
propiolamide derivatives
1
(0.2 mmol), cyanamide
(0.4 mmol, 16.8 mg). The tube was evacuated and recharged
with N2 for three times. After DMF (3.0 mL) was added,
and the tube was sealed, and the mixture was allowed to stir
at 120 or 1508C for 12 or 20 h. After completion, the mix-
ture was cooled to room temperature, 5 mL of water were
added to the tube. The solution was extracted with EtOAc
(35 mL), and the combined organic phase was dried over
anhydrous Na2SO4. After evaporation of the solvent, the
residue was isolated by silica gel CC (DCM/PE/MeOH=
5:5:1) to provide the target product (2).
Three representative examples are shown below.
8-Methyl-2-phenylbenzo[4,5]imidazo[1,2-a]pyrimidin-
4(10H)-one (2b): Eluent: DCM/PE/MeOH (5:5:1); isolated
yield: 87% (47.8 mg) for X=Br in substrate 1; 60% (33 mg)
for X=Cl in substrate 1; yellow solid; mp 297–2998C;
1H NMR (400 MHz, DMSO-d6): d=8.32 (d, J=8.2 Hz, 1H),
8.10 (dd, J=6.6, 3.1 Hz, 2H), 7.53–7.47 (m, 3H), 7.31 (s,
1H), 7.14 (d, J=8.1 Hz, 1H), 6.60 (s, 1H), 2.46 (s, 3H);
13C NMR (101 MHz, DMSO-d6): d=160.7, 160.1, 150.0,
137.5, 136.4, 130.9, 130.6, 129.1 (2CH), 127.4 (2CH),
124.1, 123.2, 115.7, 111.5, 97.3, 21.7; ESI-MS: m/z=276.1,
C17H14N3O [M+H]+.
2-(p-Tolyl)benzo[4,5]imidazo[1,2-a]pyrimidin-4(10H)-one
(2g): Eluent: DCM/PE/MeOH (5:5:1); isolated yield: 88%
1
(48.4 mg); yellow solid; mp 292–2938C; H NMR (400 MHz,
DMSO-d6): d=8.42 (d, J=8.0 Hz, 1H), 7.96 (d, J=7.9 Hz,
2H), 7.44 (s, 2H), 7.27 (dd, J=12.4, 5.5 Hz, 3H), 6.53 (s,
1H), 2.31 (s, 3H); 13C NMR (101 MHz, DMSO-d6): d=
160.6, 159.8, 149.5, 140.1, 134.2, 130.7, 129.3 (2CH), 127.0
(2CH), 126.1, 125.8, 121.8, 115.7, 111.1, 96.5, 20.9; ESI-
MS:m/z=276.1, C17H14N3O [M+H]+ .
[9] J. Ishida, K. Hattori, H. Yamamoto, A. Iwashita, K. Mi-
harab, N. Matsuoka, Bioorg. Med. Chem. Lett. 2005, 15,
4221.
Adv. Synth. Catal. 2015, 357, 3961 – 3968
ꢁ 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
3967